Project Grant R01HL178459
Award Date
6/9/25
Completion Date
2/28/29
Dollars Obligated
$579K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Toledo, OH 43614, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $880,735 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Washington. The funding supports research to investigate how cell lysis and release of leukotrienes activate type-2 immunity in the lung. Key objectives include identifying alveolar macrophages as a source of leukotriene C4, examining the roles of leukotrienes in regulating innate lymphoid cell function and downstream...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $602,955 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to National Jewish Health in Denver, Colorado. The 5-year grant, running from July 2024 to June 2029, will fund research to identify the unique functions and molecular drivers of airspace macrophage subsets during the resolution of lung inflammation and active lung repair. The primary objectives are to: 1) Test the hypothesis that a subset of airspace...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to characterize a targetable stromal factor that alters immune cell accumulation in the lung and define the downstream effects on airway epithelial cells. The $636,843 award to the Regents of the University of California, San Francisco will utilize a combination of genetic tools, human organoid platforms, and a novel pharmacologic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,788,091 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Dartmouth-Hitchcock Clinic to investigate the mechanisms underlying impaired resolution of inflammation in cystic fibrosis (CF) lung disease. The grant aims to characterize functional differences in lung macrophage subpopulations between CF patients, non-CF bronchiectasis subjects, and healthy controls, both before and after treatment with highly...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to the Regents of the University of Michigan to conduct research on the mechanisms underlying lung injury, fibrosis, and susceptibility to bacterial infections. The key objectives are to study: 1) how epithelial cell signaling regulates fibrosis and interacts with myeloid cells, 2) the impaired innate immunity against...
This federal Project Grant award, valued at $564,445.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award, effective March 1, 2025 through December 31, 2031, supports the University of Texas Health Science Center at Houston's "Hypoxia-Inflammation Program" research focused on targeting hypoxia-inducible factors (HIFs) for the treatment of heart and lung diseases. The funded...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $605,678.00 to the University of South Alabama to conduct research on a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. The research aims to explore the concept that a pathway called "BRACR" (Base Oxidation and Repair Activated Chromatin Restructuring) is a fundamental component of the...
This Project Grant award of $544,610 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the role of fibroblast-macrophage interactions and hedgehog signaling in mediating metabolic reprogramming and progression of asbestos-induced toxicity. The research will utilize human lung tissue, co-culture experiments, and transgenic mouse models to: 1) determine which macrophage subsets exhibit...
This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of neutrophil extracellular traps (NETs) in driving inflammation and infection in mucoobstructive lung diseases, including cystic fibrosis. The $756,875 award to the University of Cincinnati will support research to understand how NETs interact with the lung epithelium, leading to epithelial damage,...
This $1,659,996.00 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Southern California (USC) to investigate the role of the PDLIM2 protein in alveolar macrophage function and its impact on lung immunity, inflammation, and disease. The research aims to determine how PDLIM2 regulates the phagocytic and immune regulatory capabilities of alveolar macrophages, and how its repression promotes...